Open AccessSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
Author(s) -
Mohamed Farouk Chughlay,
Karen Barnes,
Myriam El Gaaloul,
Nada Abla,
Joerg J. Moehrle,
Paul Griffin,
Paul van Giersbergen,
Stephanie E Reuter,
Hayley B. Schultz,
Anita Kress,
Peter Tapley,
Rebecca Webster,
Timothy N. C. Wells,
James S. McCarthy,
Bridget E. Barber,
Louise Marquart,
Michelle J. Boyle,
Christian Engwerda,
Stephan Chalon
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01584-21
Subject(s) - artemether/lumefantrine , artemether , ruxolitinib , medicine , pharmacokinetics , pharmacology , lumefantrine , pharmacodynamics , tolerability , adverse effect , artemisinin , malaria , plasmodium falciparum , immunology , bone marrow , myelofibrosis
Despite repeated malaria infection, individuals living in areas where malaria is endemic remain vulnerable to reinfection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with antimalarial therapy.